Eleven Biotherapeutics Secures $20,000,000 Series A Round

Feed Type
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=ddfe2365-b062-4963-8b9d-a6c9ab681623&Preview=1
Date
5/8/2012
Company Name
Eleven Biotherapeutics
Mailing Address
215 First Street Cambridge, MA 02142
Company Description
Eleven Biotherapeutics secured Series A financing in February 2010, backed by two leading life sciences venture capital firms, Flagship Ventures and Third Rock Ventures.
Website
http://www.elevenbio.com
Transaction Type
Venture Equity
Transaction Amount
$20,000,000
Transaction Round
Series A
Proceeds Purposes
Proceeds from the financing will be used to advance Eleven’s first program, EBI-005, into clinical development while continuing to advance earlier stage programs generated by its proprietary AMP-Rx product engine.
M&A Terms
Venture Investor
Jafco Ventures
Venture Investor
Third Rock Ventures
Venture Investor
Third Rock Ventures
Venture Investor
Flagship Ventures